PriceTargets.com logo

Astria Therapeutics - ATXS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.50
  • Forecasted Upside: 135.85%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$9.54 As of 05/17/2024 01:00 AM ET
▲ +0.11 (1.17%)

This chart shows the closing price for ATXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Astria Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATXS

Analyst Price Target is $22.50
▲ +135.85% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Astria Therapeutics in the last 3 months. The average price target is $22.50, with a high forecast of $27.00 and a low forecast of $16.00. The average price target represents a 135.85% upside from the last price of $9.54.

This chart shows the closing price for ATXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Astria Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/25/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$16.00Low
5/10/2024WedbushReiterated RatingOutperform ➝ Outperform$22.00Low
4/23/2024HC WainwrightLower TargetBuy ➝ Buy$18.00 ➝ $16.00Low
3/26/2024WedbushReiterated RatingOutperform ➝ Outperform$17.00Low
3/25/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$22.00 ➝ $27.00Low
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
3/5/2024WedbushReiterated RatingOutperform ➝ Outperform$17.00Low
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
1/30/2024WedbushReiterated RatingOutperform ➝ Outperform$17.00Low
11/15/2023OppenheimerLower TargetOutperform ➝ Outperform$30.00 ➝ $25.00Low
10/13/2023WedbushLower TargetOutperform ➝ Outperform$25.00 ➝ $18.00Low
10/12/2023HC WainwrightLower TargetBuy ➝ Buy$20.00 ➝ $18.00Low
8/8/2023WedbushLower TargetOutperform ➝ Outperform$26.00 ➝ $25.00Low
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$20.00Low
3/28/2023Evercore ISIInitiated CoverageOutperform$18.00Low
2/24/2023HC WainwrightReiterated RatingBuy$20.00Low
12/19/2022HC WainwrightBoost TargetBuy$13.00 ➝ $20.00Low
11/28/2022Lifesci CapitalReiterated RatingOutperformLow
3/11/2022HC WainwrightReiterated RatingBuy$13.00High
9/29/2021Jefferies Financial GroupInitiated CoverageBuy$20.00High
9/2/2021WedbushInitiated CoverageOutperform$16.00High
8/25/2021HC WainwrightUpgradeNeutral ➝ Buy$13.00Low
5/12/2021LADENBURG THALM/SH SHInitiated CoverageBuy$36.00High
3/11/2021OppenheimerUpgradeMarket Perform ➝ Outperform$30.00High
2/1/2021HC WainwrightReiterated RatingHoldLow
11/2/2020WedbushDowngradeOutperform ➝ NeutralMedium
10/27/2020HC WainwrightDowngradeBuy ➝ NeutralN/A
10/27/2020OppenheimerDowngradeOutperform ➝ Market PerformN/A
10/1/2020HC WainwrightInitiated CoverageBuy$144.00 ➝ $144.00High
9/15/2020OppenheimerReiterated RatingBuy$360.00High
8/20/2020WedbushReiterated RatingBuy$90.00Low
6/11/2020WedbushReiterated RatingBuy$90.00Medium
4/19/2020WedbushReiterated RatingBuy$90.00Medium
3/10/2020OppenheimerReiterated RatingBuy$360.00High
3/10/2020WedbushReiterated RatingBuy$90.00High
1/8/2020WedbushReiterated RatingBuy$108.00Medium
12/16/2019WedbushReiterated RatingBuy$108.00Low
11/8/2019CitigroupLower Target$432.00 ➝ $360.00High
7/29/2019WedbushReiterated RatingOutperform$108.00High
6/24/2019WedbushSet TargetBuy$108.00High
(Data available from 5/18/2019 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 4 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 6 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024
  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
5/18/2024

Current Sentiment

  • 3 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Astria Therapeutics logo
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $9.54
Low: $9.30
High: $9.58

50 Day Range

MA: $11.67
Low: $9.00
High: $16.69

52 Week Range

Now: $9.54
Low: $4.26
High: $16.90

Volume

291,664 shs

Average Volume

823,665 shs

Market Capitalization

$523.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Astria Therapeutics?

The following Wall Street analysts have issued stock ratings on Astria Therapeutics in the last year: HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., and Wedbush.
View the latest analyst ratings for ATXS.

What is the current price target for Astria Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Astria Therapeutics in the last year. Their average twelve-month price target is $22.50, suggesting a possible upside of 135.8%. Jefferies Financial Group Inc. has the highest price target set, predicting ATXS will reach $27.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $16.00 for Astria Therapeutics in the next year.
View the latest price targets for ATXS.

What is the current consensus analyst rating for Astria Therapeutics?

Astria Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ATXS will outperform the market and that investors should add to their positions of Astria Therapeutics.
View the latest ratings for ATXS.

What other companies compete with Astria Therapeutics?

Other companies that are similar to Astria Therapeutics include Verve Therapeutics, KalVista Pharmaceuticals, Applied Therapeutics, Travere Therapeutics and Y-mAbs Therapeutics. Learn More about companies similar to Astria Therapeutics.

How do I contact Astria Therapeutics' investor relations team?

Astria Therapeutics' physical mailing address is 100 High StreetFloor 28, Boston MA, 02110. The biotechnology company's listed phone number is (617) 349-1971 and its investor relations email address is [email protected]. The official website for Astria Therapeutics is www.catabasis.com. Learn More about contacing Astria Therapeutics investor relations.